Literature DB >> 26629018

Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension.

Shaomei Guo1, Ziming Feng2.   

Abstract

AIMS: The present study aimed to perform in vitro experiments to investigate whether Galectin-3 (Gal-3) mediates the effect of platelet-derived growth factor (PDGF) on pulmonary arterial smooth muscle cells (PASMC) proliferation, apoptosis and migration, and to reveal the mechanism of how Gal-3 functions in the pathogenesis of pulmonary arterial hypertension (PAH).
METHODS: Pulmonary arterial smooth muscle cells (PASMC) were treated with various concentration of PDGF for indicated times, and the expression of Gal-3 was analyzed by western blotting. Gal-3 siRNA was transfected into the PASMC to knock down endogenous Gal-3. MTT assay was performed to examine cell proliferation. Transwell-migration assay was used to determine cell migration ability. Cell apoptosis rate was determined by flow cytometric analysis.
RESULTS: The result showed that the expression of Gal-3 protein was induced by PDGF in a dose- and a time-dependent manner. PDGF contributes to the progression of PAH by inducing cell proliferation and migration, as well as inhibiting cell apoptosis of PASMC. However, these effects of PDGF on PASMC were attenuated by Gal-3 knockdown.
CONCLUSION: The present study provided potential evidence about the role of Gal-3 in the pathophysiological mechanisms of PAH. This study firstly demonstrated that Gal-3 could be induced by PDGF in PASMC, and mediates the effect of PDGF on PASMC proliferation, apoptosis and migration, thus contributing to the pathogenesis of PAH.

Entities:  

Keywords:  Galectin-3; platelet-derived growth factor; pulmonary arterial hypertension

Year:  2015        PMID: 26629018      PMCID: PMC4658907     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  32 in total

Review 1.  Vascular smooth muscle growth: autocrine growth mechanisms.

Authors:  B C Berk
Journal:  Physiol Rev       Date:  2001-07       Impact factor: 37.312

2.  Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs.

Authors:  I A Yamboliev; W T Gerthoffer
Journal:  Am J Physiol Cell Physiol       Date:  2001-06       Impact factor: 4.249

3.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

4.  Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension.

Authors:  Brett E Fenster; Luis Lasalvia; Joyce D Schroeder; Jamey Smyser; Lori J Silveira; J Kern Buckner; Kevin K Brown
Journal:  Heart Vessels       Date:  2015-05-15       Impact factor: 2.037

5.  Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells.

Authors:  Y Tanabe; M Saito; A Ueno; M Nakamura; K Takeishi; K Nakayama
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

6.  Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.

Authors:  Neil C Henderson; Alison C Mackinnon; Sarah L Farnworth; Tiina Kipari; Christopher Haslett; John P Iredale; Fu-Tong Liu; Jeremy Hughes; Tariq Sethi
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 8.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

9.  Identification of galectin-3 as a factor in pre-mRNA splicing.

Authors:  S F Dagher; J L Wang; R J Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

Review 10.  Prognostic value of galectin-3 in patients with heart failure.

Authors:  Ivica Bošnjak; Kristina Selthofer-Relatić; Aleksandar Včev
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

View more
  7 in total

1.  Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman
Journal:  Antioxid Redox Signal       Date:  2019-03-29       Impact factor: 8.401

2.  Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension.

Authors:  Scott A Barman; Zsuzsanna Bordan; Robert Batori; Stephen Haigh; David J R Fulton
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Galectin-3 Promotes Vascular Remodeling and Contributes to Pulmonary Hypertension.

Authors:  Scott A Barman; Feng Chen; Xueyi Li; Stephen Haigh; David W Stepp; Dmitry Kondrikov; Keyvan Mahboubi; Zsuzsanna Bordan; Peter Traber; Yunchao Su; David J R Fulton
Journal:  Am J Respir Crit Care Med       Date:  2018-06-01       Impact factor: 21.405

4.  Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis.

Authors:  Scott A Barman; Xueyi Li; Stephen Haigh; Dmitry Kondrikov; Keyvan Mahboubi; Zsuzsanna Bordan; David W Stepp; Jiliang Zhou; Yusi Wang; Daniel S Weintraub; Peter Traber; William Snider; Danny Jonigk; Jennifer Sullivan; G Ryan Crislip; Joshua T Butcher; Jennifer Thompson; Yunchao Su; Feng Chen; David J R Fulton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-02-06       Impact factor: 5.464

5.  Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension.

Authors:  Peidong Wang; Jie Yang; Yanwei Yang; Zhixin Ding
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

6.  Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.

Authors:  Nikhil Hirani; Alison C MacKinnon; Lisa Nicol; Paul Ford; Hans Schambye; Anders Pedersen; Ulf J Nilsson; Hakon Leffler; Tariq Sethi; Susan Tantawi; Lise Gravelle; Robert J Slack; Ross Mills; Utsa Karmakar; Duncan Humphries; Fredrik Zetterberg; Lucy Keeling; Lyn Paul; Philip L Molyneaux; Feng Li; Wendy Funston; Ian A Forrest; A John Simpson; Michael A Gibbons; Toby M Maher
Journal:  Eur Respir J       Date:  2021-05-27       Impact factor: 16.671

Review 7.  Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension.

Authors:  Anastasia Gorelova; Mariah Berman; Imad Al Ghouleh
Journal:  Antioxid Redox Signal       Date:  2021-04-20       Impact factor: 8.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.